PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGenome editing using nanoparticle technology treats blood disorder

BioNews

Genome editing using nanoparticle technology treats blood disorder

Published 31 October 2016 posted in News and appears in BioNews 875

Author

Sarah Gregory

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Researchers have developed a novel genome-editing technology to correct the defective gene that causes the blood disorder beta-thalassemia...

Researchers have developed a novel genome-editing technique to correct the defective gene that causes the blood disorder beta-thalassemia.

The team, from Carnegie Mellon University University and Yale University, inserted synthetic genetic material called peptide nucleic acids (PNA) into the stem cells of mice to remove the beta-thalassemia mutation. This led to long-term increases in haemoglobin that were sufficient to cure the disease.

'We have developed a system that uses FDA-approved nanoparticles to deliver our PNA molecule along with donor DNA to repair a malfunctioning gene in living mice. This has not been achieved with CRISPR,' said Danith Ly, professor of chemistry at Carnegie Mellon University.

Beta-thalassaemia is a blood disorder that reduces the production of haemoglobin and leads to a lack of oxygen throughout body, causing weakness, fatigue and serious complications.

The research team designed a PNA molecule genome-editing technique specifically to target the gene associated with haemoglobin production. Using an FDA-approved vehicle, PNAs and a strand of healthy donor DNA encoding the haemoglobin gene were injected into the bone-marrow stem cells of live mice. By binding to the DNA target area, one strand of the mutant DNA was displaced and replaced by the healthy DNA, in turn engaging the cell's own DNA repair pathways and correcting the malfunctioning gene.

As reported in Nature Communications, successful genome editing was achieved in seven percent of cases, with elevated levels of haemoglobin evident for 140 days after treatment.

'The effect may only be seven percent, but that's curative,' Ly said. 'You don't need 100 percent to see the phenotype return to normal.'

PNA molecule genome editing provides a complex but efficient alternative to CRISPR. In binding to a specific area on DNA, it reduces the potential for mistakes in genome editing that are possible with CRISPR.

'[CRISPR is] so good at cutting the genome, it tends to make cuts at the wrong place, too. I think our technology is much harder to make, but we believe it's much more specific, with less off-target effects,' said Peter Glazer, a Yale University professor of genetics and co-author of the study.

Genome-editing enzymes used in CRISPR are also large and can only be used on extracted living cells, while PNA-mediated genome editing can be used in living animals because of the small size of the particles.

Despite these potential advantages, the PNA-mediated technique has yet to be tested in humans. 'That's the goal, to try to replicate this mouse model in humans,' Ly told The Washington Post.

Sources and References

  • 27/10/2016
    UPI
    Gene-editing technology may help cure blood disorders
  • 26/10/2016
    Science Daily
    New gene-editing technology successfully cures a genetic blood disorder in mice
  • 26/10/2016
    Genome web
    Yale-Led Gene Editing Study Uses PNAs to Correct Hemoglobin Gene in Human CD34 Cells, Mice
  • 26/10/2016
    Washington Post
    New gene-editing trick discovered just in time for J-LoÔÇÖs ÔÇ£CRISPRÔÇØ TV series
  • 26/10/2016
    Nature Communicatios
    In vivo correction of anaemia in ??-thalassemic mice by ??PNA-mediated gene editing with nanoparticle delivery

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
23 June 2014 • 2 minutes read

Very small beta-thalassemia gene therapy trial gets investors' blood up

by Dr Anna Cauldwell

Two patients with the serious inherited blood disorder beta-thalassemia have been able to stop blood transfusions 12 days after receiving experimental gene therapy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 September 2010 • 2 minutes read

Beta-thalassaemia patient successfully treated with 'gene therapy'

by Dr Lux Fatimathas

A patient with the genetic blood disorder beta-thalassaemia has been successfully treated using genetically-altered stem cells, according to US and French researchers...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Epigenetic sperm test sheds light on male infertility

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels


easyfundraising
amazon

This month in News

  • Popular
  • Recent
20 November 2023 • 3 minutes read

HFEA publishes recommendations for reform of fertility law

13 November 2023 • 2 minutes read

Four BRCA mutation carriers undergo removal of ovaries during C-section 

13 November 2023 • 2 minutes read

Frequent mobile phone use linked to lower sperm count in young men

6 November 2023 • 3 minutes read

Health Council of the Netherlands recommends doubling the 14-day limit on embryo research

30 October 2023 • 2 minutes read

Government to scrap additional IVF screening for same-sex couples

27 November 2023 • 2 minutes read

Research into gene therapy reveals blood cancer risk

27 November 2023 • 2 minutes read

Polish Parliament debates reinstatement of state IVF funding

27 November 2023 • 2 minutes read

Over 100,000 DNA evidence samples must be re-tested in Australia

27 November 2023 • 2 minutes read

Childhood autism associated with infertility in parents

27 November 2023 • 2 minutes read

Unintended consequence of CRISPR/Cas9 genome editing discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856